Dr. Reddy’s Laboratories Ltd
@drreddys
Followers
35K
Following
2K
Statuses
12K
A global pharmaceutical company providing access to affordable and innovative medicines because #GoodHealthCantWait. Guidelines: https://t.co/IbM7CTTCnN
Hyderabad, INDIA
Joined January 2010
Our teams are preparing for #DCATWeek. This event is a great opportunity to network, share insights, and delve into the latest innovations in the pharmaceutical and chemical industries. We're looking forward to discussing how we can contribute to your sustainable supply chain. If you're attending, let's meet! #DCAT #WeAreDrReddys #GoodHealthCantWait
0
1
2
@Mksahani_mks Hi, Thank you for getting in touch. Please could you share further information via DM using this link so our team can look into this? Regards, Team Dr. Reddy’s
1
0
0
Soil health is the foundation of food security, environmental sustainability, and human well-being. Soil is more than just dirt — it is a living, breathing ecosystem that sustains life. Our new Soil Testing Research Centre in Hyderabad recognises the ‘One Health’ philosophy - the interconnectedness of soil, plant, and human health. We invited Suman S., Head of Climate Action and Rural Livelihoods at Dr Reddy's Foundation to tell us more.
0
1
2
@ActanuragTiwari Hi, Thank you for getting in touch. Please could you share further information via DM using this link so our team can look into this? Regards, Team Dr. Reddy’s
0
0
0
Pleased to announce our collaboration with Henlius to make HLX15, the daratumumab biosimilar candidate, available to patients in the U.S. and Europe, in subcutaneous as well as intravenous formulations. HLX15 is being developed as a biosimilar of Darzalex®️ & Darzalex Faspro®️, which are indicated for the treatment of multiple myeloma. Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. The launch of our pegfilgrastim through our collaborator in the U.S. in 2023, and bevacizumab in the United Kingdom last year marked the start of our biosimilars journey in regulated markets. Last year, we also signed a collaboration with Alvotech for the commercialisation of their denosumab biosimilar in the U.S. and Europe. This latest collaboration with Henlius further progresses our regulated markets journey in biosimilars. Oncology has been a top focus therapy area for us. We look forward to leveraging our strong commercial capabilities in these markets to ensure patients receive access to best-in-class therapies and affordable treatment options. With each product, we continue our endeavour to drive access and affordability of innovative products, and our journey towards serving over 1.5 billion patients by 2030. To read more, please visit: #WorldCancerDay #GoodHealthCantWait #WeAreDrReddys #SDG3 (promoting good health and well-being)
0
2
7
@suresh_maniar Hi, Thank you for getting in touch. Please could you share further information via DM using this link so our team can look into this? Regards, Team Dr. Reddy’s
0
0
0
RT @AurigeneOnco: On #WorldCancerDay, we stand united with the global community in the fight against #cancer. We are committed to advancin…
0
4
0
@Ace_dwadler Hi, Thank you for getting in touch. Please could you share further information via DM using this link so our team can look into this? Regards, Team Dr. Reddy’s
0
0
0
Games, quizzes and activities on social impact and volunteering, Lean Ways of Working, doing more with less, testing our understanding of our Code of Compliance and Business Ethics, and products for a more sustainable lifestyle, set the stage for our Q3 quarterly global townhall at our Bachupally campus. Energised by the engagement of colleagues and led by our Management Council, we came together to take stock of the last quarter and our strategic priorities for the months ahead. A key highlight was celebrating colleagues who give back to society – a standing ovation to colleagues who have juggled their multiple roles and priorities, and volunteered their time and skills selflessly to serve those less fortunate than them. A highly motivating note on which to go into our last quarter of FY’25. #WeAreDrReddys #GoodHealthCantWait
0
2
3
The pharmaceutical sector has a key role to play in attaining our vision of ‘Viksit Bharat’ by 2047 with its own ambition of becoming a $400 billion industry by then.
0
1
2
For any queries, doctors and patients can call 1800-123-2360 (toll-free); email us at neriviodrl@porteamedical.com; WhatsApp on 6366881900; or visit
0
0
0
Our investment in multiple initiatives in these three focus areas will help us drive growth - the latest examples being our acquisition of the global consumer brand Nicotinell, joint venture for nutraceuticals with Nestle India, launch of the immuno-oncology drug Toripalimab, and opportunities in biosimilars. We also continue to focus on productivity in R&D, scaling our manufacturing and commercial capabilities, and leveraging our market access to capture opportunities while operating efficiently. #WeAreDrReddys #GoodHealthCantWait
0
0
0
Sakshi Sharma grew up in a small village in Himachal Pradesh, India. In her own words, "amidst stereotypes and financial struggles". Sakshi studied in her local village school. Her family was keen to support her and borrowed money to fund her school education. With the help of our Sashakt Scholarship run in collaboration with Dr. Reddy's Foundation @DRF_India that helps girls from under-privileged backgrounds pursue education in STEM fields, Sakshi went on to study at the prestigious St. Stephen's College, Delhi and received her Bachelor's degree in Chemistry with a 9.87 CGPA. Sakshi became the first from her family to attend university. We are proud to share that today, Sakshi is reading for a Doctorate in Philosophy (D. Phil) in Organic Chemistry at the University of Oxford! To learn more about the Sashakt scholarship, visit: #SashaktScholarship #WomenInSTEM #SDG5 (Gender Equality and Women's Empowerment) #GoodHealthCantWait #WeAreDrReddy
0
2
5
